Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
复制标题
DOI：
10.1186/1757-2215-7-57
复制
发表时间：
2014
影响因子：
4
通讯作者：
Pectasides D
中科院分区：
文献类型：
--
作者：
Aravantinos G;Pectasides D
由于血管生成增加与卵巢癌的进展有关，因此已经研究了许多抗血管生成剂，或目前正在开发，作为晚期疾病患者的潜在治疗选择。贝伐珠单抗是一种抗血管内皮生长因子的重组单克隆抗体，已获得欧洲药品管理局批准，与卡铂和紫杉醇联合用于晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌的一线治疗，以及与卡铂和吉西他滨联合用于铂敏感性卵巢癌首次复发的治疗。我们进行了一项系统的文献综述，以确定贝伐单抗在卵巢癌中的有效性和安全性数据，以及正在开发的新型抗血管生成药物。我们分析了来自随机、对照的II/III期临床试验的已发表数据，这些试验招募了接受贝伐单抗治疗的卵巢癌妇女。我们还审查了目前处于II/III期开发的新兴抗血管生成药物的可用数据，包括曲巴纳尼、阿柏西普、尼达尼布、西地尼布、伊马替尼、帕唑帕尼、索拉非尼和舒尼替尼。在4项随机、双盲、III期试验中，在标准化疗基础上加用贝伐珠单抗，无论是作为一线治疗（GOG-0218和ICON 7），还是在复发性疾病患者（OCEANS和奥雷利亚）中，均获得了显著的疗效增益。根据已发表的数据，贝伐珠单抗相关不良事件的类型和频率与这些研究中的预期一致。已经发表了一些新出现的抗血管生成药物在晚期卵巢癌III期开发中的有希望的疗效数据。需要进一步的研究来确定贝伐单抗反应的预测或预后标志物，以优化患者选择和治疗获益。新的抗血管生成药物在卵巢癌中的III期临床试验的数据正在等待中。
As increased angiogenesis has been linked with the progression of ovarian cancer, a number of anti-angiogenic agents have been investigated, or are currently in development, as potential treatment options for patients with advanced disease. Bevacizumab, a recombinant monoclonal antibody against vascular endothelial growth factor, has gained European Medicines Agency approval for the front-line treatment of advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer in combination with carboplatin and paclitaxel, and for the treatment of first recurrence of platinum-sensitive ovarian cancer in combination with carboplatin and gemcitabine. We conducted a systematic literature review to identify available efficacy and safety data for bevacizumab in ovarian cancer as well as for newer anti-angiogenic agents in development. We analyzed published data from randomized, controlled phase II/III clinical trials enrolling women with ovarian cancer to receive treatment with bevacizumab. We also reviewed available data for emerging anti-angiogenic agents currently in phase II/III development, including trebananib, aflibercept, nintedanib, cediranib, imatinib, pazopanib, sorafenib and sunitinib. Significant efficacy gains were achieved with the addition of bevacizumab to standard chemotherapy in four randomized, double-blind, phase III trials, both as front-line treatment (GOG-0218 and ICON7) and in patients with recurrent disease (OCEANS and AURELIA). The type and frequency of bevacizumab-related adverse events was as expected in these studies based on published data. Promising efficacy data have been published for a number of emerging anti-angiogenic agents in phase III development for advanced ovarian cancer. Further research is needed to identify predictive or prognostic markers of response to bevacizumab in order to optimize patient selection and treatment benefit. Data from phase III trials of newer anti-angiogenic agents in ovarian cancer are awaited.
登录
查看更多内容
影响因子：
4.7
作者：
Herr, Daniel;Sallmann, Alexandra;Wulff, Christine
通讯作者：
Wulff, Christine
影响因子：
64.5
作者：
Fischer, Christian;Jonckx, Bart;Carmeliet, Peter
通讯作者：
Carmeliet, Peter
影响因子：
6.7
作者：
Geva, E;Jaffe, RB
通讯作者：
Jaffe, RB
DOI：
10.1158/1078-0432.ccr-10-0974
发表时间：
2010-11-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Chambers SK;Clouser MC;Baker AF;Roe DJ;Cui H;Brewer MA;Hatch KD;Gordon MS;Janicek MF;Isaacs JD;Gordon AN;Nagle RB;Wright HM;Cohen JL;Alberts DS
通讯作者：
Alberts DS
DOI：
10.5402/2012/245756
发表时间：
2012-01-01
期刊：
ISRN obstetrics and gynecology
影响因子：
--
作者：
Bandiera, Elisabetta;Franceschini, Roberta;Ravaggi, Antonella
通讯作者：
Ravaggi, Antonella